Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
US Oncology Research Pfizer |
---|---|
Information provided by: | US Oncology Research |
ClinicalTrials.gov Identifier: | NCT00599313 |
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Metastatic Prostate Cancer |
Drug: Sutent |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment |
Official Title: | Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-Based Chemotherapy |
Estimated Enrollment: | 36 |
Study Start Date: | March 2007 |
Estimated Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Guru Sonpavde, MD | US Oncology Research |
Responsible Party: | US Oncology Research ( Angelica McCallister ) |
Study ID Numbers: | 2006-0012 |
Study First Received: | January 11, 2008 |
Last Updated: | January 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00599313 |
Health Authority: | United States: Institutional Review Board |
Docetaxel Prostatic Diseases Genital Neoplasms, Male Sunitinib |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site |